The interferon beta-1b 16-year long-term follow-up study: Neutralizing antibodies and clinical outcomes

The interferon beta-1b 16-year long-term follow-up study: Neutralizing antibodies and clinical outcomes

Detalles Bibliográficos
Autores principales:	Reder, A, Ebers, G, Goodin, D, Li, D, Traboulsee, A, Beckman, K, Konieczny, A
Formato:	Conference item
Publicado:	2008

Ejemplares similares

The final results of the interferon beta-1b 16-year long-term follow-up study
por: Ebers, G, et al.
Publicado: (2006)

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
por: Ebers, G, et al.
Publicado: (2009)

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
por: Reder, A, et al.
Publicado: (2010)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
por: Goodin, D, et al.
Publicado: (2012)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
por: Goodin, D, et al.
Publicado: (2012)

EDSS and MRI burden of disease predict cognitive status at 16 years: data from the long term follow-up study
por: Langdon, D, et al.
Publicado: (2007)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
por: Goodin, D, et al.
Publicado: (2012)

16-year long-term follow-up of interferon beta-1b treatment in patients with multiple sclerosis
por: Ebers, G, et al.
Publicado: (2005)

Long-term follow up of interferon-beta-1b pivotal trial RRMS patients: design issues of a 16-year follow-up study
por: Ebers, G, et al.
Publicado: (2004)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
por: Petkau, A, et al.
Publicado: (2004)

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
por: Ebers, G, et al.
Publicado: (2010)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
por: Sibley, W, et al.
Publicado: (1994)

Review: Neutralizing antibodies against interferon-beta
por: Per Soelberg Sorensen
Publicado: (2008-09-01)

Treatment of multiple sclerosis with interferon beta-1b - Reply
por: Sibley, W, et al.
Publicado: (1997)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
por: Petkau, A, et al.
Publicado: (2004)

THE INFLUENCE OF NEUTRALIZING ANTIBODIES TO INTERFERON-BETA ON PROGRESSION OF MULTIPLE SCLEROSIS
por: V. Yu. Lizhdvoy, et al.
Publicado: (2016-07-01)

CAUSE OF DEATH IN MULTIPLE SCLEROSIS PATIENTS FROM THE 21-YEAR LONG-TERM FOLLOW-UP STUDY
por: Ebers, G, et al.
Publicado: (2011)

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
por: Duquette, P, et al.
Publicado: (1996)

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study
por: Bernard Uitdehaag, et al.
Publicado: (2011-01-01)

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
por: Goodin, D, et al.
Publicado: (2012)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
por: Damiano Paolicelli, et al.
Publicado: (2016-01-01)

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies
por: Hartung Hans-Peter, et al.
Publicado: (2012-06-01)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Paul I. Creeke, et al.
Publicado: (2013-01-01)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Nicky Dunn, et al.
Publicado: (2020-10-01)

Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta.
por: Sonia Gavasso, et al.
Publicado: (2014-01-01)

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.
por: Douglas S Goodin, et al.
Publicado: (2011-01-01)

Cause of death in MS: Longterm follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study (BMJ Open (2012) 2 (e001972))
por: Goodin, D, et al.
Publicado: (2013)

Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon
por: Jane D Collier, et al.
Publicado: (2000-01-01)

Interferons in relapsing remitting multiple sclerosis.
por: Goodin, D
Publicado: (2003)

Treatment of Chronic Hepatitis B with Interferon: Long Term Follow-Up
por: Jean-Pierre Villeneuve, et al.
Publicado: (1996-01-01)

Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
por: Jenny Link, et al.
Publicado: (2014-01-01)

Experiences with interferon-beta-1b treatment in MS after three year follow-up
por: T Járdánházy, et al.
Publicado: (2002-05-01)

Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
por: Lampasona, V, et al.
Publicado: (2003)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
por: Sørensen, P, et al.
Publicado: (2010)

Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon
por: Sandro da Costa Ferreira, MD, et al.
Publicado: (2010-07-01)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
por: Cefaro Luca, et al.
Publicado: (2009-10-01)

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
por: Francis, G, et al.
Publicado: (2001)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
por: Palace, J, et al.
Publicado: (2010)

Test system for the detection of binding antibodies to interferon beta-1a for clinical use
por: E. A. Kuzminova, et al.
Publicado: (2018-02-01)

Molecular mechanism of antibody neutralization of coxsackievirus A16
por: Chao Zhang, et al.
Publicado: (2022-12-01)